Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling

Author:

Baron Murray1,Barbacki Ariane1,Man Ada2,de Vries-Bouwstra J K3,Johnson Dylan4,Stevens Wendy5,Osman Mohammed4,Wang Mianbo1,Zhang Yuqing6,Sahhar Joanne7,Ngian Gene-Siew7,Proudman Susanna89,Nikpour Mandana410,Baron M,Gyger G,Ligier S,Pope J,Larché M,Khalidi N,Massetto A,Sutton E,Man A,Rodriguez-Reyna T S,Thorne C,Fortin P R,Ikic A,Robinson D,Osman M,Jones N,LeClercq S,Docherty P,Smith D,Abu-Hakima M,Kaminska E,Fritzler M,Nikpour Mandana,Proudman Susanna,Stevens Wendy,Sahhar Joanne,Ferdowsi Nava,Morrisroe Kathleen,Ross Laura,Ngian Gene-Siew,Walker Jennifer,Roddy Janet,Host Lauren,Major Gabor,

Affiliation:

1. Lady Davis Institute for Medical Research , Montreal, Quebec, Canada

2. Rheumatology, Faculty of Medicine, University of Manitoba , Winnipeg, Manitoba, Canada

3. Department of Rheumatology, Leiden University , Leiden, The Netherlands

4. Department of Medicine, University of Alberta , Edmonton, Alberta, Canada

5. Division of Rheumatology, St. Vincent’s Hospital Melbourne , Fitzroy, Victoria, Australia

6. Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School , Boston, MA, USA

7. Monash Health , Clayton, Victoria, Australia

8. Royal Adelaide Hospital , Adelaide, South Australia, Australia

9. Discipline of Medicine, University of Adelaide , Adelaide, South Australia, Australia

10. University of Melbourne at St-Vincent Hospital , Melbourne, Fitzroy, Victoria, Australia

Abstract

Abstract Objectives Damage accrual in SSc can be tracked using the Scleroderma Clinical Trials Consortium Damage Index (DI). Our goal was to develop a prediction model for damage accrual in SSc patients with early disease. Methods Using patients with <2 years disease duration from Canada and Australia as a derivation cohort, and from the Netherlands as a validation cohort, we used group-based trajectory modelling (GBTM) to determine ‘good’ and ‘bad’ latent damage trajectories. We developed a prediction model from this analysis and applied it to patients from derivation and validation cohorts. We plotted the actual DI trajectories of the patients predicted to be in ‘good’ or ‘bad’ groups. Results We found that the actual trajectories of damage accumulation for lcSSc and dcSSc were very different, so we studied each subset separately. GBTM found two distinct trajectories in lcSSc and three in dcSSc. We collapsed the two worse trajectories in the dcSSc into one group and developed a prediction model for inclusion in either ‘good’ or ‘bad’ trajectories. The performance of models using only baseline DI and sex was excellent with ROC AUC of 0.9313 for lcSSc and 0.9027 for dcSSc. Using this model, we determined whether patients would fall into ‘good’ or ‘bad’ trajectory groups and then plotted their actual trajectories which showed clear differences between the predicted ‘good’ and ‘bad’ cases in both derivation and validation cohorts. Conclusions A simple model using only cutaneous subset, baseline DI and sex can predict damage accumulation in early SSc.

Funder

Canadian Scleroderma Research Group

Canadian Institutes of Health Research

Scleroderma Society of Ontario

Scleroderma Association of Saskatchewan, Scleroderma Manitoba

Scleroderma Society of Nova Scotia

Scleroderma Association of British Columbia

Cure Scleroderma Foundation

Canadian Blood and Marrow Transplant Group

Lady Davis Institute of Medical Research of the Jewish General Hospital

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3